Appropriate Admission in COPD Exacerbation From Emergency Department. Multicenter Study

A prospective cohort study was performed to validate the explicit criteria developed by the RAM. Other goals for the cohort study were: to predict mortality, ICU or IRCU admission, hospital length of stay, changes in symptoms and to evaluate variability among hospitals in the appropriateness of hospital admission of patients experiencing COPD exacerbations and to study variability in access to care and outcomes. Sixteen hospitals belonging to the Spanish National Health Service agreed to participate: Hospital Costa del Sol, Hospital Valme, Hospital de Motril, Corporació Sanitaria Parc Taulí, Hospital del Mar, Hospital Universitario de La Princesa, Hospital Universitario Gregorio Marañón, Hospital Universitario La Paz, Hospital de Móstoles, Hospital Marqués de Valdecilla, Hospital Santa Marina, Hospital San Eloy, Hospital Galdakao-Usansolo, Hospital Txagorritxu, Complejo Hospitalario Donostia, and Hospital Cruces.

Patients attending the EDs of any of the 16 hospitals with an exacerbation of COPD were informed of the goals of the study and invited to voluntarily participate in it. All information was kept confidential. The Institutional Review Boards of the participating hospitals approved this project. Recruitment started in June 2008 and ended in September 2010.

Patients were candidates for the study if they presented to the ED of any of the participating hospitals with symptoms consistent of an exacerbation of COPD. Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day-to-day variations, was acute in onset, and may have warranted a change in regular medication in a patient with underlying COPD. Two possible presentations were considered:

Existing COPD. Patients were considered to have been previously diagnosed with COPD if they had a FEV1/forced vital capacity (FVC) quotient <70%, and a negative bronchodilation test with FEV1 change <200 mL and under 15% of the baseline value.

New COPD. Patients not previously diagnosed with COPD but in whom the disease was suspected were also eligible for inclusion in the study. This included smokers or former smokers of more than 15 packs per year with dyspnea, cough, or expectoration for more than three months per year, and experiencing symptoms resembling a clinical manifestation compatible with COPD exacerbation. The diagnosis had to be confirmed by spirometry within 60 days after the index episode at a time when the patient was stable, i.e., the absence of any increase in symptoms or changes in background therapy. If a diagnosis of COPD was not confirmed, the patient was excluded from the study.

Patients were excluded from the study if they had COPD complicated by a comorbidity such as pneumonia, pneumothorax, or pulmonary embolism; lung cancer; or left cardiac insufficiency. Other exclusion criteria included a diagnosis of asthma, extensive bronchiectasis, sequelae of tuberculosis, pleural thickening, or restrictive diseases. Patients who did not wish to participate were also excluded.

Data collected for the cohort study A substantial amount of clinical and other data were needed to meet the objectives of the IRYSS-CAS. Data from several time points were needed: during the patient's evaluation in the ED; at the time the decision was made to hospitalize the patient or discharge him or her to home; in the medical ward (if needed); and during post-hospitalization or post-discharge follow-up. It must be noted that ED physicians were not asked to gather any information other than what they would usually collect for a patient experiencing an exacerbation of COPD. Instead, trained data managers gathered data from hospital and primary care medical records using a manual of instructions that aimed to standardize data collection.

Some of the information required a review of the patient's medical records. Patients admitted to the hospital were interviewed at 1 and 7 days after admission. Patients discharged from the ED to home were interviewed by telephone at, around, 1 and 7 days after discharge. All patients were interviewed by telephone 60 days after the index event.

In the ED. As is true for almost any encounter in the ED, substantial information is gathered for a patient experiencing an exacerbation of COPD. The main data collected were those related to the patient's respiratory function (gasometry, respiratory rate, dyspnea), consciousness level measured by the Glasgow Coma scale, background, and presence of other pathologies as those recorded in the Charlson Comorbidity Index.

At the time of decision making. Data collected at the ED decision time was related to the patient's respiratory status at that moment as well as variables needed to create the appropriateness scenarios, determine the severity of the exacerbation, and evaluate other study criteria .

In the hospital. For patients admitted to the hospital, we collected data directly from the patient's medical record and from a direct interview with him or her from the first day after admission until discharge. Patients were interviewed about their general health status (response to question 1 of the Short Form 36 (SF-36) questionnaire[16]), degree of dyspnea, based on the Medical Research Council Dyspnea Index[17], physical activity level (based on a scale employed previously in various studies and also completed the EuroQol-5D. Patients were also asked about social support and level of functional dependency. This information was recorded in the first 24 hours after arrival to the ED and at discharge.

Following discharge to home from the ED. Among patients discharged to home from the ED, telephone interviews were conducted around 1 day, 7 days, and 60 days after discharge to assess the level of dyspnea, physical activity, and general health (see previous description), the use of and response to medications, need for supplemental oxygen, the need for visits to the patient's primary care physician, subsequent ED visits or hospital readmissions, vital status, presence of other symptoms, social support, and level of functional dependency.

During follow-up. Data collected during follow-up included general health status (SF-36 question), degree of dyspnea, physical activity level, and quality of life, all as previously described. Readmission within 30 days of the index exacerbation for the same reason, or readmission for any reason between 31 and 60 days after the index exacerbation was recorded, as were complications, including all signs, symptoms, syndromes or diseases, which appeared or worsened during the 60-day observation period attributable to COPD or its treatment. For all patients with known COPD, additional variables collected from medical records include baseline severity of COPD as measured by FEV1; hospital admissions during the previous 12 months; baseline therapy (inhaled long-acting beta agonist, long-acting anticholinergics, inhaled corticosteroid and/or supplemental oxygen), the presence of associated diseases such as diabetes, hypertension, ischemic heart disease and/or valve disease, cor pulmonale, peptic ulcer disease, psychiatric disorders, rheumatic disease, history of stroke or deep vein thrombosis, and others needed to determine the Charlson Comorbidity Index.

Mortality information at one year was also recorded for all patients.